Logo image of DCTH

DELCATH SYSTEMS INC (DCTH) Stock Fundamental Analysis

NASDAQ:DCTH - Nasdaq - US24661P8077 - Common Stock - Currency: USD

12.11  +0.05 (+0.41%)

After market: 12.11 0 (0%)

Fundamental Rating

5

Taking everything into account, DCTH scores 5 out of 10 in our fundamental rating. DCTH was compared to 191 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for DCTH as it has an excellent financial health rating, but there are worries on the profitability. DCTH is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DCTH has reported negative net income.
In the past year DCTH has reported a negative cash flow from operations.
In the past 5 years DCTH always reported negative net income.
In the past 5 years DCTH always reported negative operating cash flow.
DCTH Yearly Net Income VS EBIT VS OCF VS FCFDCTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.45%, DCTH is in line with its industry, outperforming 41.88% of the companies in the same industry.
DCTH's Return On Equity of -38.38% is in line compared to the rest of the industry. DCTH outperforms 53.93% of its industry peers.
Industry RankSector Rank
ROA -34.45%
ROE -38.38%
ROIC N/A
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DCTH Yearly ROA, ROE, ROICDCTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

DCTH has a better Gross Margin (83.37%) than 94.24% of its industry peers.
In the last couple of years the Gross Margin of DCTH has grown nicely.
DCTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
DCTH Yearly Profit, Operating, Gross MarginsDCTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

8

2. Health

2.1 Basic Checks

DCTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DCTH has more shares outstanding
Compared to 5 years ago, DCTH has more shares outstanding
DCTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DCTH Yearly Shares OutstandingDCTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DCTH Yearly Total Debt VS Total AssetsDCTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 22.26 indicates that DCTH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 22.26, DCTH belongs to the best of the industry, outperforming 96.34% of the companies in the same industry.
There is no outstanding debt for DCTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.26
ROIC/WACCN/A
WACC9.24%
DCTH Yearly LT Debt VS Equity VS FCFDCTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 12.01 indicates that DCTH has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.01, DCTH belongs to the best of the industry, outperforming 95.81% of the companies in the same industry.
DCTH has a Quick Ratio of 10.88. This indicates that DCTH is financially healthy and has no problem in meeting its short term obligations.
DCTH has a Quick ratio of 10.88. This is amongst the best in the industry. DCTH outperforms 94.76% of its industry peers.
Industry RankSector Rank
Current Ratio 12.01
Quick Ratio 10.88
DCTH Yearly Current Assets VS Current LiabilitesDCTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

DCTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.97%, which is quite impressive.
DCTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 1698.21%.
DCTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 88.10% yearly.
EPS 1Y (TTM)67.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.08%
Revenue 1Y (TTM)1698.21%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%2701.48%

3.2 Future

DCTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.69% yearly.
DCTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.79% yearly.
EPS Next Y107.08%
EPS Next 2Y64.29%
EPS Next 3Y47.06%
EPS Next 5Y28.69%
Revenue Next Year132.57%
Revenue Next 2Y89.29%
Revenue Next 3Y61.97%
Revenue Next 5Y42.79%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DCTH Yearly Revenue VS EstimatesDCTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
DCTH Yearly EPS VS EstimatesDCTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200M -400M -600M -800M -1B

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DCTH. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 174.60, which means the current valuation is very expensive for DCTH.
67.02% of the companies in the same industry are more expensive than DCTH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.38, DCTH is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 174.6
DCTH Price Earnings VS Forward Price EarningsDCTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCTH Per share dataDCTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
DCTH's earnings are expected to grow with 47.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y64.29%
EPS Next 3Y47.06%

More info and screens

0

5. Dividend

5.1 Amount

DCTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DELCATH SYSTEMS INC

NASDAQ:DCTH (4/25/2025, 8:01:08 PM)

After market: 12.11 0 (0%)

12.11

+0.05 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-06 2025-03-06/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners39%
Inst Owner Change0.07%
Ins Owners2.88%
Ins Owner Change0.52%
Market Cap404.84M
Analysts85
Price Target22.95 (89.51%)
Short Float %2.74%
Short Ratio1.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-179.46%
Min EPS beat(2)-488.34%
Max EPS beat(2)129.41%
EPS beat(4)2
Avg EPS beat(4)-95.85%
Min EPS beat(4)-488.34%
Max EPS beat(4)129.41%
EPS beat(8)3
Avg EPS beat(8)-65.24%
EPS beat(12)4
Avg EPS beat(12)-48.17%
EPS beat(16)7
Avg EPS beat(16)-33.16%
Revenue beat(2)2
Avg Revenue beat(2)6.2%
Min Revenue beat(2)4.98%
Max Revenue beat(2)7.43%
Revenue beat(4)4
Avg Revenue beat(4)24.71%
Min Revenue beat(4)4.98%
Max Revenue beat(4)45.68%
Revenue beat(8)4
Avg Revenue beat(8)0.93%
Revenue beat(12)7
Avg Revenue beat(12)8.33%
Revenue beat(16)9
Avg Revenue beat(16)23.68%
PT rev (1m)3.23%
PT rev (3m)5.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)112.5%
EPS NY rev (1m)0%
EPS NY rev (3m)126.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)24.04%
Revenue NY rev (1m)7.51%
Revenue NY rev (3m)7.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 174.6
P/S 10.88
P/FCF N/A
P/OCF N/A
P/B 5.89
P/tB 5.89
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)0.07
Fwd EY0.57%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS1.11
BVpS2.06
TBVpS2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.45%
ROE -38.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.37%
FCFM N/A
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
F-Score6
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 417.16%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.01
Quick Ratio 10.88
Altman-Z 22.26
F-Score6
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)208.01%
Cap/Depr(5y)235.23%
Cap/Sales(3y)4.01%
Cap/Sales(5y)12.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.08%
EPS Next Y107.08%
EPS Next 2Y64.29%
EPS Next 3Y47.06%
EPS Next 5Y28.69%
Revenue 1Y (TTM)1698.21%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%2701.48%
Revenue Next Year132.57%
Revenue Next 2Y89.29%
Revenue Next 3Y61.97%
Revenue Next 5Y42.79%
EBIT growth 1Y67.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200.98%
EBIT Next 3Y81.86%
EBIT Next 5YN/A
FCF growth 1Y38.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.22%
OCF growth 3YN/A
OCF growth 5YN/A